Effectiveness and Safety Study of Peripheral Balloon Dilatation Catheter in Percutaneous Transluminal Angioplasty(PTA) Procedure

NCT01849601 — Not applicable, Completed, 167 participants, Acotec Scientific Co., Ltd

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Prospective, Multicenter and Single-arm Target Value Clinical Study on the Efficacy and Safety of Peripheral Balloon Dilatation Catheter in PTA Procedure

RegistryNCT01849601
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, single group, masking: none, treatment
Enrollment167 (Actual)
SponsorAcotec Scientific Co., Ltd (Industry)
ConditionsPeripheral Arterial Disease
Interventionspercutaneous transluminal angioplasty balloon catheter (Device)
Datesstart 2012-12-01, primary completion 2013-03-01, completion 2013-03-01, first posted 2013-05-08, last updated 2015-03-23
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
All trials for Peripheral Arterial Disease All trials of percutaneous transluminal angioplasty balloon catheter

-Summary

The purpose of this study is to determine whether the peripheral balloon dilatation catheter (trade name: Iris) is safe an effective in PTA procedure.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
PTA catheterExperimentalDevice: percutaneous transluminal angioplasty balloon catheter
  • percutaneous transluminal angioplasty balloon catheter (Device), also known as PTA catheter, trade name: Iris

+Outcome measures

Primary outcomes

  • technical success rate of PTA procedure [instant]: 1. successfully pass lesion(s) 2. successfully dilate lesion(s)( diameter of balloon reach at least 90% of the nominal diameter) 3. successfully retrieve The definition of technical success rate of PTA procedure is that, all of the above 3 point are successful

Secondary outcomes

  • safety assessment [day 2 to day 10 after procedure or hospital discharge]: 1. relevant balloon complications occurred during procedure(failure of balloon inflation, rupture of the balloon, failure of balloon deflation, failure of withdrawn, catheter fracture, etc.). 2. Relevant major vascular complications occurred during procedure (rupture of blood vessels and acute vascular occlusion caused by dilation).

+Eligibility

Sex: All, ages: 18 Years to 80 Years

Inclusion Criteria:

* Age: 18 yrs - 80 yrs.
* patients with iliac and / or femoral artery atherosclerotic lesions
* Rutherford grade of 1-5;
* Target lesion stenosis≥70% (visual estimation) (proportion of Trans-Atlantic Inter-Society Consensus(TASC) B, C and D grade lesions not less than 60% )
* Patients being able to understand the purpose of the test, and being volunteered to participate in and sign the informed consent.

Exclusion Criteria:

* Patients not suitable for receiving interventional surgeries of lower limb arteries for treatment;
* Patients require intervention of lesions besides unilateral iliac and femoral artery lesions at the same time;
* Patients have been involved in clinical trials of other drugs or medical devices within the past three months;
* Patient is unable or unwilling to participate in this trial;
* Patients with serious heart and brain, liver and other vital organs failure;
* Patients with life expectancy less than 6 months;
* Pregnant women.

+Locations (1)

FacilityCityCountryStatus
Wei GuoBeijingChina